Cargando…
Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain
The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-syn...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545725/ https://www.ncbi.nlm.nih.gov/pubmed/28094812 http://dx.doi.org/10.1038/tp.2016.257 |
_version_ | 1783255476481294336 |
---|---|
author | Purves-Tyson, T D Owens, S J Rothmond, D A Halliday, G M Double, K L Stevens, J McCrossin, T Shannon Weickert, C |
author_facet | Purves-Tyson, T D Owens, S J Rothmond, D A Halliday, G M Double, K L Stevens, J McCrossin, T Shannon Weickert, C |
author_sort | Purves-Tyson, T D |
collection | PubMed |
description | The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-synthesising enzyme, tyrosine hydroxylase (TH), have not identified consistent changes. We hypothesise that dopamine dysregulation in schizophrenia could result from changes in expression of dopamine synthesis enzymes, receptors, transporters or catabolic enzymes. Gene expression of 12 dopamine-related molecules was examined in post-mortem midbrain (28 antipsychotic-treated schizophrenia cases/29 controls) using quantitative PCR. TH and the synaptic dopamine transporter (DAT) proteins were examined in post-mortem midbrain (26 antipsychotic-treated schizophrenia cases per 27 controls) using immunoblotting. TH and aromatic acid decarboxylase (AADC) mRNA and TH protein were unchanged in the midbrain in schizophrenia compared with controls. Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups. However, DAT protein was significantly increased in putatively treatment-resistant cases of schizophrenia compared to putatively treatment-responsive cases. Midbrain monoamine oxidase A (MAOA) mRNA was increased, whereas MAOB and catechol-O-methyl transferase mRNAs were unchanged in schizophrenia. We conclude that, whereas some mRNA changes are consistent with increased dopamine action (decreased DAT mRNA), others suggest reduced dopamine action (increased MAOA mRNA) in the midbrain in schizophrenia. Here, we identify a molecular signature of dopamine dysregulation in the midbrain in schizophrenia that mainly includes gene expression changes of molecules involved in dopamine synthesis and in regulating the time course of dopamine action. |
format | Online Article Text |
id | pubmed-5545725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55457252017-08-07 Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain Purves-Tyson, T D Owens, S J Rothmond, D A Halliday, G M Double, K L Stevens, J McCrossin, T Shannon Weickert, C Transl Psychiatry Original Article The dopamine hypothesis of schizophrenia posits that increased subcortical dopamine underpins psychosis. In vivo imaging studies indicate an increased presynaptic dopamine synthesis capacity in striatal terminals and cell bodies in the midbrain in schizophrenia; however, measures of the dopamine-synthesising enzyme, tyrosine hydroxylase (TH), have not identified consistent changes. We hypothesise that dopamine dysregulation in schizophrenia could result from changes in expression of dopamine synthesis enzymes, receptors, transporters or catabolic enzymes. Gene expression of 12 dopamine-related molecules was examined in post-mortem midbrain (28 antipsychotic-treated schizophrenia cases/29 controls) using quantitative PCR. TH and the synaptic dopamine transporter (DAT) proteins were examined in post-mortem midbrain (26 antipsychotic-treated schizophrenia cases per 27 controls) using immunoblotting. TH and aromatic acid decarboxylase (AADC) mRNA and TH protein were unchanged in the midbrain in schizophrenia compared with controls. Dopamine receptor D2 short, vesicular monoamine transporter (VMAT2) and DAT mRNAs were significantly decreased in schizophrenia, with no change in DRD3 mRNA, DRD3nf mRNA and DAT protein between diagnostic groups. However, DAT protein was significantly increased in putatively treatment-resistant cases of schizophrenia compared to putatively treatment-responsive cases. Midbrain monoamine oxidase A (MAOA) mRNA was increased, whereas MAOB and catechol-O-methyl transferase mRNAs were unchanged in schizophrenia. We conclude that, whereas some mRNA changes are consistent with increased dopamine action (decreased DAT mRNA), others suggest reduced dopamine action (increased MAOA mRNA) in the midbrain in schizophrenia. Here, we identify a molecular signature of dopamine dysregulation in the midbrain in schizophrenia that mainly includes gene expression changes of molecules involved in dopamine synthesis and in regulating the time course of dopamine action. Nature Publishing Group 2017-01 2017-01-17 /pmc/articles/PMC5545725/ /pubmed/28094812 http://dx.doi.org/10.1038/tp.2016.257 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Original Article Purves-Tyson, T D Owens, S J Rothmond, D A Halliday, G M Double, K L Stevens, J McCrossin, T Shannon Weickert, C Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain |
title | Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain |
title_full | Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain |
title_fullStr | Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain |
title_full_unstemmed | Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain |
title_short | Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain |
title_sort | putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545725/ https://www.ncbi.nlm.nih.gov/pubmed/28094812 http://dx.doi.org/10.1038/tp.2016.257 |
work_keys_str_mv | AT purvestysontd putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain AT owenssj putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain AT rothmondda putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain AT hallidaygm putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain AT doublekl putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain AT stevensj putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain AT mccrossint putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain AT shannonweickertc putativepresynapticdopaminedysregulationinschizophreniaissupportedbymolecularevidencefrompostmortemhumanmidbrain |